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Abstract: Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven colorectal cancer (CRC) is
notorious to target with drugs and has shown ineffective treatment response. The seeds of Pharbitis
nil, also known as morning glory, have been used as traditional medicine in East Asia. We focused
on whether Pharbitis nil seeds have a suppressive effect on mutated KRAS-driven CRC as well as
reserving muscle cell functions during CRC progression. Seeds of Pharbitis nil (Pharbitis semen) were
separated by chromatography and the active compound of Pharbitis semen (PN) was purified by
HPLC. The compound PN efficiently suppressed the proliferation of mutated KRAS-driven CRC cells
and their clonogenic potentials in a concentration-dependent manner. It also induced apoptosis of
SW480 human colon cancer cells and cell cycle arrest at the G2/M phase. The CRC related pathways,
including RAS/ERK and AKT/mTOR, were assessed and PN reduced the phosphorylation of AKT
and mTOR. Furthermore, PN preserved muscle cell proliferation and myotube formation in cancer
conditioned media. In summary, PN significantly suppressed mutated KRAS-driven cell growth and
reserved muscle cell function. Based on the current study, PN could be considered as a promising
starting point for the development of a nature-derived drug against KRAS-mutated CRC progression.
Keywords: Pharbitis nil; colorectal cancer; KRAS; muscle function
1. Introduction
Colorectal cancer (CRC) is the third most diagnosed cancer worldwide. Recent statistics showed
CRC caused 832,000 deaths and nearly 1.6 million new cases were diagnosed [1]. Among the various
CRCs, Kirsten rat sarcoma viral oncogene homolog (KRAS) genetic mutation driven-CRC are known
to be difficult to target, and prone to drug-induced side effects [2,3]. Mutated KRAS proteins cause
persistent activation of GTP, which endlessly send signals to the RAS/extracellular signal–regulated
kinases (RAS/ERK) or protein kinase B/mammalian target of rapamycin (AKT/mTOR) cell regulation
pathways [2]. ERK or mTOR proteins activate transcription factors involved in cell death, cell cycle
progression, and transcription [2,4]. To inhibit RAS activation, antibody therapy was developed to
target EGFR, such as Cetuximab, but various drug-resistance issues were documented [5–7]. Therefore,
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novel medicinal substances with effective anti-cancer properties are needed and plant-derived foods or
medicinal plants can offer potential means.
Several natural products have exhibited anti-CRC activity. For example, Danshen (Salvia miltiorrhiza)
improved the survival rate of patients with colorectal cancer [8]. Triterpenoids from Rhus chinensis
Mill [9], protopine from Nandina domestica [10], Paris saponin VII from Trillium tschonoskii [11] and
protein hydrolysates from Fenugreek (Trigonella foenum graecum) [12] suppressed the proliferation and
induced apoptosis of CRC cells. Additionally, rosemary (Rosmarinus officinalis) inhibited CRC growth
by inducing necrosis [13]. However, limited studies have examined the effects of natural extracts
targeting mutated KRAS-driven CRC and none of these studies tested the efficacy of these extracts on
muscle function. In our previous study, Cordyceps militaris germinated soybeans suppressed mutated
KRAS-driven CRC via the RAS/ERK pathway [14]. Phellinus linteus grown on germinated brown rice
increased the sensitivity of Cetuximab to inhibit KRAS-CRC progression both in vitro and in vivo [15].
Although the two natural compounds have anti-CRC activities, more medicinal substances are needed
to target the notorious and drug-resistant nature of mutated KRAS-driven CRC.
Morning glory (Pharbitis nil) is a well-known ornamental plant, and its seeds have been used in
traditional medicine to treat various cancers and inflammatory diseases in Korea, China, and Japan [16].
Recent studies have demonstrated its suppressive effects on breast cancer [17], lung cancer [18] and
gastric cancer cells [19]. In addition, the seed of Pharbitis nil is the main constitute of the approved
drug, DA-9701 (Motilitone) [20]. DA-9701 is a botanical drug for treating functional dyspepsia and
composed of the seed of Pharbitis nil and Corydalis tuber. Therefore, we anticipated its safety on human
and can be adapted for therapies in a relatively short timeframe if proven its efficiency. In view of
its anticancer effects, we considered the active compound of Pharbitis semen (PN) may inhibit the
proliferation and progression of mutated KRAS-driven CRC without inducing serious side effects.
In addition to the suppressive effect of PN on CRCs, we evaluated the effect of compound PN on
muscle cell function. During the course of CRC, cachexia, a complex syndrome showing severe muscle
weight loss, is often accompanied with CRC progression and worsened treatment therapies [21–23].
Therefore, treating cachexia becomes an important combinational therapy in the treatment of CRCs.
We mimicked cancer-associated environment with conditioned media and evaluated the effect of PN
on muscle cells.
In the present study, the anticancer activity of PN was investigated by examining its
anti-proliferation and clonogenic features in five different CRC cell models. Cell cycle and apoptotic
analyses were performed, and the changes in RAS/ERK and AKT/mTOR pathways were investigated.
Finally, we assessed the effect of the compound PN on muscle cell proliferation and function.
2. Results and Discussion
2.1. PN Suppressed Colorectal Cancer Cell Progress
To investigate the anti-proliferative effects of PN on mutated KRAS-driven CRC, KRAS mutated
SW480 and HCT116 cells as well as KRAS-wild type (WT) HT29 and WiDr were evaluated. Cells were
treated with PN at 0, 0.1, 0.5, 1, 2, or 4 µg/mL and incubated for 48 or 72 h in triplicate. Cetuximab
which has been used to treat mutated KRAS-driven CRCs was used as a control. Figure 1A summarized
the proliferation profiles. PN inhibited cell growth in a concentration dependent manner in mutated
KRAS-driven cell lines at 48 and 72 h. At 72 h, SW480 viability was decreased to 41.6 ± 1.0% when
treated with PN at 2 µg/mL and to 26.0 ± 4.5% when treated with 4 µg/mL PN. When compared to
control drug of Cetuximab, PN showed higher suppressive effect from 2 µg/mL concentration. Data also
indicated that KRAS mutated cell lines responded more sensitively on PN treatment compared to KRAS
wild type cells of HT-29 and WiDr. In KRAS wild type cells, PN treatment did not show statistical
decrease on proliferation at 48 h. The IC50 values of KRAS mutated cells at 72 h are 1.74 and 2.78 µg/mL
on SW480 and HCT116 cells, whereas they are 4.14 and 4.46 µg/mL on KRAS WT cells of HT29 and
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WiDr cells. IC50 values of KRAS mutated cells are relatively low compared to other natural extract
such as pogostone (HCT116: 18.7 ± 1.93 µg/mL) [24].
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Figure 1. (A) PN suppressive effect on KRAS-mutated colorectal cancer cells of SW480 (KRASG12V) 
and HCT116 (KRASG13D), and KRAS-wild types CRCs of HCT116 and WiDr. Cells were treated for 48 
and 72 h under PN treatment (0, 0.1, 0.5, 1, 2 and 4 μg/mL) and Cetuximab (30 μg/mL). IC50 values are 
calculated. Results are presented as means  S.D. of three independent experiments. *p < 0.05, **p < 
0.01, ***p < 0.001. (B) Representative colorectal cancer cell images under PN treatment (0, 0.5, 1 and 4 
μg/mL). Blue represents the DAPI-stained cell nuclei, and the propidium iodide-stained dead cells 
are red. Scale bar = 500 μm. DAPI, 4',6-diamidino-2-phenylindole; PI, propidium iodide. 
Figure 1. (A) PN suppressive effect on KRAS-mutated colorectal cancer cells of SW480 (KRASG12V)
and HCT116 (KRASG13D), and KRAS-wild types CRCs of HCT116 and WiDr. Cells were treated
for 48 and 72 h under PN treatment (0, 0.1, 0.5, 1, 2 and 4 µg/mL) and Cetuximab (30 µg/mL). IC50
values are calculated. Results are presented as means ± S.D. of three independent experiments.
* p < 0.05, ** p < 0.01, *** p < 0.001. (B) Representative colorectal cancer cell images under PN treatment
(0, 0.5, 1 and 4 µg/mL). Blue represents the DAPI-stained cell nuclei, and the propidium iodide-stained
dead cells are red. Scale bar = 500 µm. DAPI, 4′,6-diamidino-2-phenylindole; PI, propidium iodide.
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Cells were stained with DAPI and PI for live and dead cell detection. Cell nuclei were stained
with DAPI (blue) which represent all cells, and dead cells were stained with PI (red). Most cells in
control group were stained with DAPI and little PI staining after 48 h of cultivation indicating most
cells are alive (Figure 1B). In contrast, cells treated with PN began to appear dead PI stained cells from
0.5 µg/mL.
By assessing clonogenic potentials, we evaluated if PN inhibited tumorogeneity. As shown in
Figure 2, PN dose-dependently suppressed colony formation by the KRAS mutated cell lines SW480,
and HCT116. For example, PN treatment at 1 µg/mL suppressed SW480 cell colony formation to
26%. Surprisingly, almost no colony formation was observed by KRAS mutated CRCs treated with
4 µg/mL of PN. In contrast, HT29 and WiDr colonies are still visible even at the highest concentration.
These findings show that PN sensitively suppress proliferation rate and tumor forming abilities in
the long-term aspects of mutated KRAS-driven CRC cells. Further mechanistic and molecular studies
were performed with SW480 cells at PN concentrations ranging from 0.1 to 4 µg/mL.
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Seeds of Pharbitis nil contains several bioactive compounds such as polysaccharides [16], 
pharbitin (resin glycosides) [25], anthocyanins, diterpenoids [26], triterpene saponins [27], 
pharbilignan C [17], neolignane, and onoterpene glycosi es [28]. Pharbilignan C has been reported 
to induce human breast cancer cell apoptosis via the mitochondria-medicated intrinsic pathway [17], 
and lignans exhibited anti-inflammatory and anti-cancer activities [29]. Thus, the observed 




Figure 2. (A) Clonogenic potential after the PN treatment (0, 1 and 4 μg/mL) on KRAS-mutated 
colorectal cell lines of SW480 (KRASG12V) and HCT116 (KRASG13D) and KRAS-WT cells of HT29 and 
WiDr. (B) Relative colony numbers upon the PN treatment were calculated compared to the control. 
Results are presented as means  S.D. of three independent experiments. *p < 0.05, **p < 0.01, ***p < 
0.001. 
2.2. PN Induced Apoptosis and Cell Cycle Arrest in the G2/M Phase 
Figure 2. (A) Clon genic potential fter the PN treatment (0, 1 and 4 µg/mL) on KRAS-mutated
colorectal cell lines of SW480 (KRASG12V) and HCT116 ( ) and KRAS-WT cells of HT29
and WiDr. (B) Relative colo y numbers upon the PN reatment were c lculated compared to the
control. Results are presented as means ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01,
*** p < 0.001.
Seeds of Pharbitis nil contains several bioactive compounds such as polysaccharides [16], pharbitin
(resin glycosides) [25], anthocyanins, diterpenoids [26], triterpene saponins [27], pharbilignan C [17],
neolignane, and monoterpene glycosides [28]. Pharbilignan C has been reported to induce human
breast cancer cell apoptosis via the mitochondria-medicated intrinsic pathway [17], and lignans
exhibited anti-inflammatory and anti-cancer activities [29]. Thus, the observed suppressive effects of
PN on CRC cell-lines may have been due to the presence of these functional compounds.
2.2. PN Induced Apoptosis and Cell Cycle Arrest in the G2/M Phase
To investigate the mechanism of cell death in mutated KRAS-driven human colorectal cell lines
induced by PN, we analyzed apoptosis and cell cycles. For detecting apoptotic cells, Annexin V-FITC
and PI staining was used. Annexin V binds specifically to a phosphatidylserine residue that is
externalized by cells undergoing apoptosis. As seen in Figure 3, PN substantially increased the
percentage of apoptotic cells in a concentration-dependent manner. Early (Annexin V FITC+/PI−) and
late (Annexin V FITC+/PI+) apoptosis counts were increased up to 28.6 ± 1.4 % and 40.2 ± 2.7 % at 2 or
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Figure 3. (A) Flow cytometric apoptosis images PN treatment using Annexin V-FITC/PI staining. 
SW480 cells were stained with Annexin V-FITC/PI upon PN treatment (0, 0.1, 0.5, 1, 2, and 4 μg/mL). 
(B) The percentage of apoptotic cells upon the PN treatment were compared. Asterisks (*) indicate 
statistical differences compared to untreated control (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; Student’s 
t test. Statistical differences among the experimental groups were confirmed via one-way ANOVA 
test. FITC, fluorescein isothiocyanate; PI, propidium iodide.  
To investigate the mechanism of cell death in mutated KRAS-driven human colorectal cell lines 
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and PI staining was used. Annexin V binds specifically to a phosphatidylserine residue that is 
externalized by cells undergoing apoptosis. As seen in Figure 3, PN substantially increased the 
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late (Annexin V FITC+/PI+) apoptosis counts were increased up to 28.6 ± 1.4 % and 40.2 ± 2.7 % at 2 or 
4 μg/mL PN treatment for 48 h, respectively. These observations suggest PN inhibits CRC 
proliferation by inducing apoptosis.  
Cell cycle is progressed into four phases: gap1 (G1), DNA synthesis (S), gap2 (G2) and mitosis 
(M). Arresting cancer cells at a certain stage are often viewed as therapeutic targets [30]. The cell cycle 
after exposing SW480 cells at concentrations of 0.5–4 μg/mL of PN was investigated. As seen in Figure 
4A, cell cycle analysis showed PN concentration-dependently induced accumulation in the G2/M 
phase and a concomitant reduction in the G0/G1 phase. For example, the proportions of cells in the 
G2/M phase after treatment with 1 or 4 μg/mL of PN were 28.5 ± 0.3 % and 41.2 ± 6.7 %, respectively, 
which demonstrated PN inhibited cell growth by arresting cells in the G2/M phase. Then, we 
investigated expression levels of the cdc2 and cyclin B1, which are proteins for cell cycle progression 
from G2/M to G0/G1. Indeed, western blot images revealed that PN concentration-dependently 
reduced the levels of both proteins (Figure 4B). 
PN was found to arrest cells in the G2/M phase to reduce the number of cells in the G0/G1 phase 
(Figure 4), therefore less cells enter into mitosis. This is interesting in that most of the cell cycle arrests 
caused by natural extracts reported to date have occurred in the G0/G1 or G2/M stages. [21,31,32]. 
For example, pogostone induced G0/G1 arrest in a KRAS mutated HCT116 cell-line [24].  
Figure 3. (A) Flow cytometric apoptosis images PN treatment using Annexin V-FITC/PI staining.
SW480 cells were stained with Annexin V-FITC/PI upon PN treatment (0, 0.1, 0.5, 1, 2, and 4 µg/mL).
(B) The percentage of apoptotic cells upon the PN treatment were compared. Asterisks (*) in icate
statistical differences compared to untreated control (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001; Student’s
t test. Statistical differences a ong the experimental groups were confirmed via one-way ANOVA test.
FITC, fluorescein isothiocyanat ; PI, propidium iodide.
Cell cycle is progressed into four phases: gap1 (G1), DNA synthesis (S), gap2 (G2) and mitosis (M).
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Figure 4. (A) Cell cycle analysis upon PN treatment (0, 0.5, 1, 2, and 4 μg/mL). Images represent the 
SW480 cell response under PN treatment. Percentages in each cell cycle phase (G0/G1, S, G2/M) are 
calculated and G2/M phase are increased as concentration dependent manner. Asterisks indicates 
statistical differences compared to untreated control through Student’s t-test (*p < 0.05, **p < 0.01, ***p 
< 0.001). (B) Expression of G2/M phase related proteins of cdc2 and cyclin B1 upon PN treatment. 
HSP90 was used as a loading control and the protein intensity was analyzed in triplicate. The ratios 
of cdc2/HSP90 and cyclin B1/HSP90 were calculated and analyzed by Student t-test *p < 0.05, **p < 
0.01, ***p < 0.001. 
2.3. Inhibition of the AKT/mTOR pathway enhanced PN-induced cell death 
Mutated KRAS-driven CRC signals are through the ERK/MEK or AKT/mTOR pathways [3,4]. 
During mutated KRAS-driven CRC progression, mutant RAS constitutively activates ERK/MEK or 
AKT/mTOR phosphorylation, and as a result promotes cancer cell proliferation. To determine 
Figure 4. (A) Cell cycle analysis upon PN treatment (0, 0.5, 1, 2, and 4 µg/mL). Images represent the
SW480 cell response under PN treatment. Percentages in each cell cycle phase (G0/G1, S, G2/M) are
calculated and G2/M phase are increased as concentration dependent manner. Asterisks indicates
statistical differences compared to untreated control through Student’s t-test (* p < 0.05, ** p < 0.01,
*** p < 0.001). (B) Expression of G2/M phase related proteins of cdc2 and cyclin B1 upon PN treatment.
HSP90 was used as a loading control and the protein intensity was analyzed in triplicate. The ratios of
cdc2/HSP90 and cyclin B1/HSP90 were calculated and analyzed by Student t-test * p < 0.05, ** p < 0.01,
*** p < 0.001.
2.3. Inhibition of the AKT/mTOR Pathway Enhanced PN-Induced Cell Death
Mutated KRAS-driven CRC signals are through the ERK/MEK or AKT/mTOR pathways [3,4].
During m t te - ri en progression, m tan RAS constitutively activates ERK/MEK or
AKT/mTOR phosphorylation, and as a result promotes cancer cell pr liferation. To determine whether
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SW480 growth inhibition by PN is regulated by RAS/ERK or AKT/mTOR pathways, cells are treated
with PN for 48 h and protein levels of KRAS, p-ERK, p-AKT, and p-mTOR were assessed by western
blot. As shown in Figure 5, PN significantly and concentration-dependently suppressed p-AKT
and p-mTOR phosphorylation. For example, the expression of p-AKT was reduced to 0.31 in PN
4 µg/mL treated cells as compared with 1.0 in the non-treated control. The level of KRAS and ERK
phosphorylation was similar in all groups as observed in Figure 5. These results demonstrated that
PN suppressed CRC progression predominantly via the AKT/mTOR pathway. The AKT/mTOR and
ERK/MEK pathways are known to be major regulatory signaling pathways that relate to CRC cell
proliferation, metabolism, and survival [2,4,33]. Our observations suggest that the antitumor effect of
PN is caused by reductions in the phosphorylations of AKT and mTOR.
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Figure 5. (A) Representative western blot images of KRAS, HSP90, phospho-p42/44 MAPK (phospho-
ERK1/2), phospho-AKT, phospho-mTOR protein expression in SW480 cells treated with the 
compound PN (0, 0.5, 1, 2 and 4 μg/mL). (B) The ratios of KRAS/HSP90, phospho-ERK1/2/HSP90, and 
phospho-AKT/GAPDH, phospho-mTOR/GAPDH were calculated and compared to the control. (N= 
3; mean SEM, *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test).  
2.4. PN Restores Muscle Cell Function During Cancer Progression 
During cancer progression, skeletal muscles are weakened which causes progressive functional 
impairment, called cachexia [21–23]. Accordingly, it is important aspects that agents targeting cancers 
do not adversely affect muscle cells. Thus, we examined the proliferation and function of muscle cells 
of myoblast, treated with different concentrations of PN (0, 0.1, 0.5, 1, 2, or 4 μg/mL) for 48 or 72 h. In 
Figure 6A, PN did not inhibit cell proliferation up to 2 μg/mL concentrations. After 72 h of treatment 
with 2 or 4 µg/mL of PN, cell viabilities remained at 97% and 61% of non-treated control levels. Next, 
Figure 5. (A) Representative western blot images of KRAS, HSP90, phospho-p42/44 MAPK
(phospho-ERK1/2), phospho-AKT, phospho-mTOR protein expression in SW480 cells treated with
the compound PN (0, 0.5, 1, 2 and 4 µg/mL). (B) The ratios of KRAS/HSP90, phospho-ERK1/2/HSP90,
and phospho-AKT/GAPDH, phospho-mTOR/GAPDH were calculated and compared to the control.
(N = 3; mean SEM, * p < 0.05, ** p < 0.01, *** p < 0.001; Student’s t test).
2.4. PN Restores Muscle Cell Function during Cancer Progression
During cancer progression, skeletal muscles are weakened which causes progressive functional
impairment, called cachexia [21–23]. Accordingly, it is important aspects that agents targeting cancers
do not adversely affect muscle cells. Thus, we examined the proliferation and function of muscle
cells of myoblast, treated with different concentrations of PN (0, 0.1, 0.5, 1, 2, or 4 µg/mL) for 48 or
72 h. In Figure 6A, PN did not inhibit cell proliferation up to 2 µg/mL concentrations. After 72 h of
treatment with 2 or 4 µg/mL of PN, cell viabilities remained at 97% and 61% of non-treated control
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levels. Next, we examined if PN affected muscle functions of myotube formation by inducing myogenic
differentiation. Phenotypes were detected by myosin heavy chain (MyHC) immunostaining and
fusion indices were calculated. Surprisingly, PN treatment did not inhibit myogenic differentiation as
determined by MyHC staining and fusion indices (Figure 6B,C). In fact, fusion indices even improved
at all PN treated groups. Our data suggest that PN has a beneficial effect on muscle cell function.
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Figure 6. (A) C2C12 cells were treated with different PN concentrations (0, 0.1, 0.5, 1, 2 and 4 μg/mL) 
for 48 and 72 h. Results are presented as means  S.D. of 3 independent experiments, *p < 0.05, **p < 
0.01, ***p < 0.001. (B) Immunofluorescence microscopy for the expression of the myogenic markers 
Myosin heavy Chain (MyHC) and DAPI. Myogenesis was induced in differentiation media and 
treated for 5 days with different PN concentration (0, 0.5 and 1 μg/mL). (C) Fusion indexes were 
calculated as the % of the nuclei inside myotubes compared to the total number of nuclei. (N= 3 
independent experiments; mean SEM, *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test). Between 
experimental groups, statistical difference was found via one-way ANOVA (### < 0.001). (D) 
Representative images of myotube formation on cancer conditioned media upon PN treatment (0, 0.1, 
0.5 and 1 μg /mL). Myotube was detected with MyHC (green) immunostaining and nuclear 
counterstained DAPI (blue). Scale bar = 200 μm. (E) Fusion index were calculated as the % of the nuclei 
inside myotubes compared to the total number of nuclei. (Data were from three independent 
experiments; mean SEM, *p < 0.05; Student’s t test). 
Because PN did not impair and rather supported C2C12 myogenic differentiation into myotube 
formation, we further investigated if PN could attenuate conditioned media (CM)-mediated muscle 
function impairment. In Figure 6D,E, reduced myotube numbers and MyHC expression were 
Figure 6. (A) C2C12 cells were treated with different PN concentrations (0, 0.1, 0.5, 1, 2 and 4 µg/mL) for
48 and 72 h. Results are presented as means ± S.D. of 3 independent experiments, * p < 0.05, ** p < 0.01,
*** p < 0.001. (B) Immunofluorescence microscopy for the expression of the myogenic markers Myosin
heavy Chain (MyHC) and DAPI. Myogenesis was induced in differentiation media and treated for 5 days
with different PN concentration (0, 0.5 and 1 µg/mL). (C) Fusion indexes were calculated as the % of the
nuclei inside myotubes compared to the total number of nuclei. (N= 3 independent experiments; mean
SEM, * p < 0.05, ** p < 0.01, *** p < 0.001; Student’s t test). Between experimental groups, statistical difference
was found via one-way ANOVA (### p < 0.001). (D) Representative images of myotube formation on
cancer conditioned media upon PN treatment (0, 0.1, 0.5 and 1 µg /mL). Myotube was detected with MyHC
(green) immunostaining and nuclear counterstained DAPI (blue). Scale bar = 200 µm. (E) Fusion index
were calculated as the % of the nuclei inside myotubes compared to the total number of nuclei. (Data were
from three independent experiments; mean SEM, * p < 0.05; Student’s t test).
Because PN did not impair and rather supported C2C12 myogenic differentiation into myotube
formation, we further investigated if PN could attenuate conditioned media (CM)-mediated muscle
function impairment. In Figure 6D,E, reduced myotube numbers and MyHC expression were observed
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on PN-untreated control, which indicated cancer environment significantly impaired muscle cell
function. However, PN-treatment rescued C2C12 muscle cell dysfunctions. In detail, increased
myotube formation and MyHC expression compared to the SW480 control CM were observed
(Figure 6D,E).
During cancer progression, cancer-associated cachexia is common [21], and one of the problems
posed by anti-cancer drugs is that they impair normal cell proliferation and function. Therefore,
the maintenance of muscle cell proliferation and myogenic differentiation are important aspects at the
cancer therapeutic development. Interestingly, we found PN did not impair muscle cell proliferation,
but actually restored muscle cell function.
3. Materials and Methods
3.1. Preparation of PN from the Seeds of Pharbitis nil
PN was prepared as previously reported [34]. In brief, dried seeds of Pharbitis nil (1 kg) were
ground. Then, ground Pharbitis nil was immersed in methanol (MeOH) at room temperature for 48 h
and extracted. The MeOH extract was filtered with 5 µm filter paper and concentrated using a rotary
evaporator (Tokyo Rikakikai, Tokyo, Japan). To purify compound PN, the MeOH extract (5 g) was
dissolved in 50% MeOH and chromatographed on a Diaion HP-20 column by the gradient MEOH (50%,
80%, 100%, each fraction 500 mL). The 100% MeOH fraction (800 mg) was further chromatographed on
reversed-phase C-18 and Sephadex LH-20 column using 100% MeOH as mobile phase, simultaneously.
The 250 mg of purified compound PN was confirmed by high performance liquid chromatography
(HPLC) in our previous study.
3.2. Cell Culture and Treatment
The human CRC cell-lines, SW480, HCT116, HT29 and WiDR were purchased from the American
Type Culture Collection (Rockville, MD, USA). G12V KRAS mutated SW480 (KRASG12V), G13D KRAS
mutated HCT116 (KRASG13D), KRAS wild types of HT29 and WiDR were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS; Invitrogen), and 1% penicillin-streptomycin (P/S; Sigma,
St. Louis, MO, USA). C2C12 cells were purchased from ATCC and cultured in DMEM (Dulbecco’s
modified Eagle’s medium) containing 10% FBS and 1% P/S in a 5% CO2 atmosphere at 37 ◦C.
3.3. Cell Proliferation by MTS Assay
An MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay (Promega, Fitchburg, WA, USA) was used to determine the anti-proliferative effect of PN on
CRC cell lines and its toxic effect on C2C12 muscle cells. For each cell line tested, 2 × 104 cells per
well were seeded onto 96-well plates and allowed to attach. Cells were treated with PN at 0.1, 0.5, 1,
2, or 4 µg/mL and incubated for 48 and 72 h. Cetuximab of 30 µg/mL was added as a control. MTS
solution (20 µL) was then added and cells were incubated at 37 ◦C for 1 h. Absorbance were measured
at 490 nm (Model 550, Bio-Rad, Hercules, CA, USA). The experiments were performed in triplicate.
IC50 values (concentrations that inhibited cell growth by 50%) were compared.
3.4. DAPI/PI Staining
Cells were treated with PN for 48 h, fixed with 4% paraformaldehyde (Sigma), washed with
PBS, and stained with DAPI (4′,6-diamidino-2-phenylindole, Sigma) to detect cell nuclei and with PI
(propidium iodide, Sigma) to detect dead cells in the dark. Stained cells were then observed under a
fluorescence microscope (EVOS®, Thermo Scientific, Waltham, MA, USA).
3.5. Clonogenic Assay
Human CRC cell lines were seeded at 1 × 103 cell/well onto six-well plates. After cells had
completely attached, they were treated with 1 or 4 µg/mL of PN, and 10 days later, fixed with
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4% paraformaldehyde for 10 min, dried, and stained with 0.05% crystal violet (Sigma) for 15 min.
The experiments were performed in triplicate.
3.6. Cell Apoptosis Analysis
Human CRC cells were treated with PN at 0.1, 0.5, 1, 2, or 4 µg/mL for 48 h, harvested, stained
with Annexin V-FITC and PI for 15 min in the dark, according to the manufacturer’s instructions
(BD Biosciences, San Jose, CA, USA). Apoptotic cells were analyzed by flow cytometry (FC 500,
Beckman Coulter, Indianapolis, IN, USA). The experiments were performed in triplicate.
3.7. Cell Cycle Analysis
Cell cycles were analyzed by flow cytometry in triplicate. Cells were seeded, treated with PN at
0.5, 1, 2, or 4 µg/mL for 24 h, detached, fixed in ice-cold 70% ethanol, and stained with PI solution
containing RNase for 10 min in the dark. Cell cycle distributions were analyzed by flow cytometry
(FC 500).
3.8. Western Blotting
Western blot analysis was performed in triplicate as previously described [14]. Cells were treated
with compound PN (0.5–4µg/mL) for 48 h and detached with trypsin-EDTA. Proteins were isolated with
RIPA buffer containing protease inhibitors (Sigma) and quantified using a bicinchoninic acid (BCA) assay
(Thermo Scientific). Proteins were separated in precast SDS-PAGE gels (10%, Invitrogen) and transferred
to membranes using the iBlot system (Thermo Scientific). Membranes were blocked with 5% skimmed
milk in Tris buffered saline (TBS) and incubated with the following primary antibodies overnight at 4
◦C; cdc2, cyclin B1, HSP90, phospho-mTOR, GAPDH, KRAS, phospho-ERK1/2, and phospho-AKT.
Membranes were then washed and incubated with HRP-conjugated goat anti-rabbit or anti-mouse
antibodies (Pierce, Rockford, IL, USA). Densitometric analysis was performed using ImageJ software
(NIH, Bethesda, MD, USA) and ratios of proteins versus the loading control were calculated.
3.9. Myogenic Differentiation
C2C12 myoblasts were seeded onto six-well plates (4 × 104 cells/well) in triplicate and cultured for
2 days in DMEM. Myogenesis was induced by culturing cells in differentiation medium (DMEM, 2%
Horse serum, 1% P/S) containing PN at 0.5, 1 µg/mL for 5 days [35]. Differentiated muscle cells were
immunostained for fast myosin heavy chain (f-MyHC, a marker of terminal myogenic differentiation),
fixed with 4% paraformaldehyde, blocked with 5% goat serum, and incubated at room temperature
with myosin 4 monoclonal antibody (MF20)-Alexa Fluor 488 (Thermo Scientific) overnight at 4 ◦C.
The nuclei were visualized by staining with DAPI (Sigma) for 10 min. Total cell nuclei and nuclei
within f-MyHC-positive myofibers in at least 15 fields of three replicate platings were counted by using
ImageJ. Myotube fusion indices were calculated by expressing the number of cells expressing f-MyHC
(green) as a percentage of total nuclei (DAPI, blue) [35,36].
3.10. Preparation of SW480-Conditioned Media
To prepare conditioned media, SW480 cells were cultured on the 100 mm cell culture dish with
the concentration of 5 × 104 cells/seeding. After 24 h, cells were washed with 1× PBS and changed to
serum-free DMEM. Upon one day of incubation, media were collected and supernatant parts were
filtered through 0.2 µm syringe filter for conditioned media (CM).
3.11. C2C12 Myogenic Differentiation in Cancer Conditioned Media
To investigate the effect of PN on C2C12 myogenic differentiation under during cancer progression,
conditioned media (CM) were applied as follows. First of all, C2C12 myoblasts were seeded onto
six-well plates (4 × 104 cells/well) and cultured for 2 days in regular DMEM. After cells are attached,
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the mixture of CM and differentiation media (2% horse serum in DMEM) with the ratio of 1:3 were
added and PN with the concentrations of 0.1, 0.5 and 1 µg/mL were treated.
3.12. Statistical Analysis
Results were reported as means ± standard errors of means (SEM) of experiments performed in
triplicate. Comparisons among experimental groups were performed by one-way ANOVA using SPSS
ver. 12.0 (SPSS, IBM, USA). p-values of <0.05 were deemed significant.
4. Conclusions
The results of the present study showed two beneficial effect of PN on KRAS-mutated CRC. Firstly,
it significantly suppressed KRAS-mutated CRC progression. Cell proliferation and clonogenic potential
were decreased at relatively low concentrations via apoptosis and G2/M phase arrest. The mechanism
responsible for the effects of PN may be associated with the AKT/mTOR signaling pathway. Secondly,
PN rescued muscle cells dysfunction under cancer progression. Collectively, our results provide
support for the incorporation of PN into therapeutic regimens targeting mutated KRAS-driven CRC.
For future research, the toxicity and efficacy of PN needs to be performed in animal studies.
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